The rational use of methotrexate in rheumatoid arthritis and other rheumatic diseases

British Journal of Rheumatology

Volumn 36, Issue 11, 1997, Pages 1196-1204

  Furst, D E ^a  

^a BENAROYA RESEARCH INSTITUTE   (United States)

Author keywords

Juvenile chronic arthritis; Kinetics; Mechanisms; Methotrexate; Psoriasis; Rheumatoid arthritis

Indexed keywords

METHOTREXATE;

BLOOD TOXICITY; DRUG EFFICACY; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; LIVER CIRRHOSIS; LUNG TOXICITY; MALAISE; NEPHROTOXICITY; PRIORITY JOURNAL; PSEUDOLYMPHOMA; PSORIATIC ARTHRITIS; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; STOMATITIS; TERATOGENICITY;

EID: 0031426332     PISSN: 02637103     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/36.11.1196     Document Type: Review

References (70)

1. Bacon PA, Salmon M. Modes of action of second line agents. Scand J Rheumatol 1987;64(suppl):17-24.
2. Segal R, Yoron M, Tarlackovsky B. Methotrexate: mechanism of action in rheumatoid arthritis. Semin Arthritis Rheum 1990;20:190-9.
3. Kremer JM. The mechanism of action of methotrexate in rheumatoid arthritis: the search continues. J Rheumatol 1994;21:1-5.
4. Cronstein BN, Merrill JT. Mechanisms of the effects of methotrexate. Bull Rheum Dis 1996;45:6-8.
5. Herman RA, Veng-Pedersen P, Hoffman J, Koehnke R, Furst DE. Pharmacokinetics of low-dose methotrexate in rheumatoid arthritis patients. J Pharm Sci 1989;78:165-71.
6. Anaya JM, Fahre D, Bressolle F et al. Effects of etodolac on methotrexate pharmacokinetics in patients with rheumatoid arthritis. J Rheumatol 1994;21:203-8.
7. Irendt JW, Browne BA, Fiacco GP, Stale AD, Mock D. A comparison of low does methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. J Rheumatol 1993;20:1845-9.
8. Galivan J. Evidence for the cytotoxic activity of the polyglutamate derivatives of methotrexate. Mol Pharmacol 1980;17:105-10.
9. Kremer J, Galivan J, Streckfuss A, Kamen B. Methotrexate analysis in blood and liver of rheumatoid arthritis patients: association with hepatic folate deficiency and formation of polyglutamate. Arthritis Rheum 1986;29:832-5.
10. Furst DE, Koehnke R, Riggs C, La Brecque R, Mitros FA. Prospective longitudinal study of liver biopsies in 40 RA patients on MTX followed for 6.5 years. Arthritis Rheum 1993;29(suppl.):S19.
11. Chabner BA, Young RC. Threshold methotrexate concentration for in vivo inhibition of DNA synthesis in normal and tumorous target tissues. J Clin Invest 1973;52:1804-11.
12. Bologna C, Edno L, Anaya JM et al. Methotrexate concentration in synovial membrane and trabecular and cortical bone in rheumatoid arthritis patients. Arthritis Rheum 1994;37:1770-3.
13. Kremer JM, Petrillo GF, Hamilton RA. Examination of pharmacokinetic variables in a cohort of patients with rheumatoid arthritis beginning therapy with methotrexate compared with a cohort receiving the drug for a mean of 81 months. J Rheumatol 1995;22:41-4.
14. Albertioni F, Flato B, Seideman P et al. Methotrexate in juvenile rheumatoid arthritis. Eur J Clin Pharmacol 1995;47:507-11.
15. Karen G, Ferrayzini G, Sohl H et al. Chronopharmacology of methotrexate pharmacokinetics in childhood leukemia. Chrono Int 1992;9:434-8.
16. Furst DE. Clinical pharmacology of low-dose methotrexate. In: Wilske WS, ed. Methotrexate therapy in rheumatic disease. New York: Marcel Dekker, 1990:25-33.
17. Hendel J, Nyfars A. Nonlinear renal elimination kinetics of methotrexate due to saturation of renal tubular reabsorption. Eur J Clin Pharmacol 1984;26:121-4.
18. Janknegt R, Nube NJ, Van den Hoogen F, Oldenhof HGW, Steenhoek A, Vree TB. Pharmacokinetics of methotrexate in continuous ambulatory peritoneal dialysis. Pharm Weekbl 1988;10:86-9.
19. Nurnberg B, Koehnke R, Solsky M, Hoffman J, Furst DE. Biliary elimination of low-dose methotrexate in humans. Arthritis Rheum 1990;33:989-1002.
20. Ertmann R, Landbeck G. Effect of oral cholestyramine on elimination of high-dose methotrexate. J Cancer Res Oncol 1985;110:48-50.
21. Lilly MB, Omura GA. Clinical pharmacology of oral intermediate-dose methotrexate with or without probenecid. Cancer Chemother Pharmacol 1985;15:220-2.
22. Furst DE. Practical clinical pharmacology and drug interactions of low-dose methotrexate therapy in rheumatoid arthritis. Br J Rheumatol 1995;34(suppl.): 20-5.
23. Rooney RW, Furst DE, Koehnke R, Burmeister L. Aspirin is not associated with more toxicity than other NSAID in patients with RA treated with methotrexate. J Rheumatol 1993;20:1297-1302.
24. Lafforgue P, Monjanel-Mouterde S, Durand A, Catalin J, Acguaviva P-C. Is there an interaction between low doses of corticosteroids and methotrexate in patients with rheumatoid arthritis? A pharmacokinetic study in 33 patients. J Rheumatol 1993;20:263-7.
25. Fries JF, Singh G, Lenert L, Furst DE. Aspirin, hydroxychloroquine, and hepatic enzyme abnormalities with methotrexate in RA. Arthritis Rheum 1990;33: 1611-9.
26. Morgan SL, Baggott JE, Vaughn WH et al. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 1985;28:721-30.
27. Morgan SL, Baggott JE, Vaughn JE, Vaughn WH, Austin JS, Veitch TA et al. Supplementation with folic acid during methotrexate therapy for RA. Ann Intern Med 1994;121:833-41.
28. Williams HJ, Willkens RF, Samuelson CO Jr, Alarcon GS, Guttadauria M et al. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum 1985;28:721-30.
29. Weinblatt ME, Collyn JS, Fox DA, Fraser PA, Holdeworth DE et al. Efficacy of low-dose methotrexate in RA. N Engl J Med 1985;312:818-22.
30. Anderson PA, West SG, O'Dell JR, Via CS, Claypool RG et al. Weekly pulse methotrexate in RA. Clinical and immunologic effects in a randomized, double-blind study. Ann Intern Med 1985;103:489-96.
31. Thompson RN, Watts C, Edelman J, Esdaile J, Russell AS. A controlled two centre trial of parenteral methotrexate therapy in the treatment of refractory RA. J Rheumatol 1984;11:760-3.
32. Furst DE, Koehnke R, Burmeister LF, Kohler J, Cargill I. Increasing methotrexate effect with increasing dose in the treatment of resistant RA. J Rheumatol 1989;16:313-20.
33. Tugwell P, Bennett K, Bell M, Gant M. Methotrexate in RA. Ann Intern Med 1989;110:581-3.
34. Jeurissen ME, Boerbooms AM, Van de Putte LBA, Doesburg WH, Mulder J et al. Methotrexate versus azathioprine in the treatment of rheumatoid arthritis: a 48-week randomized, double-blind trial. Arthritis Rheum 1991;34:961-72.
35. Rau R, Hernorn G, Karger T, Menninger E, Elhardt D, Schmitt J. A double-blind, randomized parallel trial of intramuscular methotrexate and gold sodium thiomalate in early erosive rheumatoid arthritis. J Rheumatol 1991;18:328-33.
36. Weinblatt ME, Kaplan H, Germain BF, Merriman RC, Solomon SD et al. Low-dose methotrexate compared with auranofin in adult rheumatoid arthritis. Arthritis Rheum 1990;33:330-8.
37. Weinstein A, Bujak D, Marlowe S, Parke A, Zebrockie F, Peterson M. Methotrexate or gold in early rheumatoid arthritis. Arthritis Rheum 1987;30(suppl.):S94 (Abstract).
38. Morassut R, Goldstein R, Cyr M, Karsh J, McKendry RJR Jr. Gold sodium thiomalate compared to low dose methotrexate in the treatment of rheumatoid arthritis - a randomized double-blind 26-week trial. J Rheumatol 1989;16:302-6.
39. Hamdy H, McKendry RJR Jr, Mierins E, Liver JA. Low-dose methotrexate compared with azathioprine in the treatment of rheumatoid arthritis. A twenty-four week controlled clinical trial. Arthritis Rheum 1987;30:361-8.
40. Williams HJ, Ward JR, Reading JC, Brooks RH, Clegg DO et al. Comparison of auranofin, methotrexate and the combination of both in the treatment of rheumatoid arthritis. Arthritis Rheum 1992;35:259-69.
41. Willkens RF, Urowitz MB, Stabelin DM, McKendry RJR Jr, Berger RG et al. Comparison of azathioprine, methotrexate and the combination of both in the treatment of rheumatoid arthritis. Arthritis Rheum 1992;35:849-56.
42. Tugwell P, Pincus T, Yocum D, Stein M, Gluck O et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N Engl J Med 1995;333:137-41.
43. Ferraz MB, Pinkeiro GRC, Helfenstein M, Albuquerque E, Rezende C et al. Combination therapy with methotrexate and chloroquine in rheumatoid arthritis. Scand J Rheumatol 1994;23:231-6.
44. O'Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W et al. Treatment of RA with methotrexate alone, sulfasalazine and hydroxychloroquine or a combination of all three. N Engl J Med 1996;334:1287-91.
45. Rau R, Herborn G, Karger T, Wercher D. Retardation of radiologic progression in RA with MTX therapy. Arthritis Rheum 1991;34:1236-44.
46. Felson DT, Anderson JJ, Meenan RF. Use of short- term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. Arthritis Rheum 1992;35:1117-25.
47. Wolfe F. The epidemiology of drug treatment failure in RA. Baillière's Clin Rheumatol 1995;9:619-32.
48. Furst DE. Proposition: methotrexate should not be the first second-line agent to be used if NSAID fail. Semin Arthritis Rheum 1990;20:69-75.
49. Alarcon GS, Lopez-Mendez A, Watter J, Russell AS, Furst DE et al. Radiographic evidence of disease progression in methotrexate drug-treated RA. J Rheumatol 1992;19:1868-73.
50. Black RL, O'Brien WM, Van Scott EJ et al. Methotrexate in psoriatic arthritis. J Am Med Assoc 1964;189:743-7.
51. Willkens RF, Williams HJ, Ward JR et al. Randomized, double-blind, placebo-controlled trial of low-dose methotrexate in psoriatic arthritis. Arthritis Rheum 1984;27:376-81.
52. Lechure E, Giannini EH, Cassidy JT, Brewer EJ, Shaikov A, Maximov A et al. Comparative efficacy and safety of advanced drug therapy in children with juvenile rheumatoid arthritis. Semin Arthritis Rheum 1993;23:34-46.
53. Rothenburg RJ, Graziano FM, Grandone JT et al. The use of methotrexate in steroid-resistant SLE. Arthritis Rheum 1988;31:612-15.
54. Kozarek RA, Patterson DJ, Gelfand MD et al. Methotrexate induces clinical and histological remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989;110:353-6.
55. Creemers MC, Franssen MJ, Van de Putte LBA et al. Methotrexate in severe ankylosing spondylitis: an open study. J Rheumatol 1955;22:1104-9.
56. Nesher G, Sonnenblick M. Steroid-sparing medications in temporal arteritis - report of three cases and review of 174 reported patients. Clin Rheumatol 1994;13:289-92.
57. Sneller MC, Hoffman GS, Talar-Williams C et al. An analysis of 42 Wegener's granulomatosis patients treated with methotrexate and prednsione. Arthritis Rheum 1995;38:608-13.
58. Van de Hoogen FHJ, Boerbooms AMT, Van de Putte LBA. Methotrexate treatment in scleroderma. Am J Med 1989;87:116-7.
59. Furst DE, Kremer JM. Methotrexate in rheumatoid arthritis. Arthritis Rheum 1988;31:305-14.
60. Kremer JM. Long-term prospective study of RA patients receiving methotrexate therapy: update after 13.3 years. Arthritis Rheum 1993;39(suppl.):S102 (Abstract).
61. Furst DE. Cyclosporin, leflunomide and nitrogen mustard in innovative treatment approaches for RA. Clin Rheumatol 1990;4:575-94.
62. Bergquist SR, Felson DYT, Prashker MJ, Friedberg KA. The cost-effectiveness of liver biopsies in RA treated with methotrexate. Arthritis Rheum 1995;38: 326-33.
63. Kremer JM, Alarcón GS et al. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum 1994;37:316-28.
64. Songsiridej N, Furst DE. Methotrexate - the rapidly acting drug. Clin Rheumatol 1990;4:575-94.
65. IARC Working Group. Methotrexate. IARC Monogr 1982;26:282-5.
66. Hausknecht RU. Methotrexate and misoprostol in terminating early pregnancy. N Engl J Med 1995;333: 537-40.
67. Wyss E, Kuhn M, Luzi H-P, Reinhart WH. Fatal Pneumocystis carinii pneumonia under low-dose methotrexate-prednisolone therapy for RA. Schweiz Rundsch Med 1994;83:449-52.
68. Godeau B, Coutant-Perronne V, Huong DLT et al. Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases. J Rheumatol 1994;21:246-51.
69. Furst DE, Erikson N, Clute L, Koehnke R, Burmeister LF, Kohler JA. Adverse experience with methotrexate during 176 weeks of a long-term prospective trial in patients with RA. J Rheumatol 1990;17:1628-35.
70. Shiroky JB, Frost A, Skelton JD, Haegert DG, Newkirk MM, Neville C. Complications of immunosuppression associated with weekly low-dose methotrexate. J Rheumatol 1991;181:1171-5.